Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28949648 | 0.79 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL31389482 | 0.78 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL24291983 | 0.78 | JAK2 (0.33) | NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL24290451 | 0.75 | FAAH (0.41) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL24290453 | 0.74 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL31289211 | 0.72 | DDB1 (0.43) | NPC1RAB9ASMN1; SMN2MGLLALDH1A1 | |
| SCHEMBL24289502 | 0.72 | FAAH (0.38) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL24289998 | 0.70 | NPC1 (0.35) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL24289510 | 0.68 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2FAAHMGLL | |
| SCHEMBL30945257 | 0.67 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | NPC1 716/4885RAB9A 2065/4885SMN1; SMN2 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.